Jane Seagal

Jane is Vice President of Antibody Discovery at AlivaMab Discovery Services. She has over a decade of experience in antibody discovery for biologics drug development using in vivo approaches.

Prior to joining AlivaMab Discovery Services, Jane established and led the In Vivo Antibody Discovery and Antibody Sequencing teams at AbbVie, where she also headed a cross-functional team of scientists responsible for biologics discovery and screening funnel strategies. Jane introduced and implemented multiple technology platforms including hybridoma automation, novel immunization protocols, digital hybridoma concept and direct antibody cloning from human patient samples. These technological advances had a direct impact on the biologics pipeline, helping scientists approach targets once thought undruggable by biologics and resulting in several current clinical candidate molecules. Jane has led projects across diverse therapeutic areas including oncology, immunology and virology.

Jane earned her PhD in immunology at the Technion—Israel Institute of Technology in Haifa, Israel, and completed post-doctoral research at Harvard Medical School.